BIOMARIN PHARMACEUTICAL INC 8-K

What Happened

• BioMarin Pharmaceutical Inc. filed an 8-K on June 4, 2026 reporting results of its June 2, 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the 2017 Equity Incentive Plan to add 7,650,000 shares of common stock, effective immediately. All ten director nominees were elected to the board, KPMG LLP was ratified as independent auditor for 2026, and the advisory vote on named executive officer compensation was approved.

Key Details

• Record date and turnout: 193,270,028 shares entitled to vote (record date April 7, 2026); 175,813,292 shares present or represented by proxy at the meeting.
• Equity Plan amendment: approved to increase shares reserved by 7,650,000; vote — For: 158,561,867; Against: 5,480,380; Abstain: 152,003; Broker non-votes: 11,619,042.
• Director elections: all ten nominees elected; votes in favor ranged from 144,380,101 to 163,115,633.
• Other votes: KPMG LLP ratified as auditor (For: 170,867,335; Against: 4,850,526; Abstain: 95,431). Advisory "say-on-pay" passed (For: 142,742,800; Against: 21,287,767).

Why It Matters

• The approved increase of 7.65 million shares expands the pool available for employee and executive equity awards, which can support hiring and retention but may dilute existing shareholders over time.
• Re-election of the full board and ratification of KPMG maintain leadership and audit continuity.
• The advisory approval of executive compensation indicates shareholder support, though a measurable minority voted against it (over 21 million votes), which investors may watch for future governance engagement.